The use of heat transfer principles in designing optimal diathermy and cancer treatment modalities

1982 ◽  
Vol 25 (6) ◽  
pp. 823-834 ◽  
Author(s):  
Ashley F. Emery ◽  
K.Michael Sekins
2020 ◽  
Vol 20 (2) ◽  
pp. 130-145 ◽  
Author(s):  
Keywan Mortezaee ◽  
Masoud Najafi ◽  
Bagher Farhood ◽  
Amirhossein Ahmadi ◽  
Dheyauldeen Shabeeb ◽  
...  

Cancer is one of the most complicated diseases in present-day medical science. Yearly, several studies suggest various strategies for preventing carcinogenesis. Furthermore, experiments for the treatment of cancer with low side effects are ongoing. Chemotherapy, targeted therapy, radiotherapy and immunotherapy are the most common non-invasive strategies for cancer treatment. One of the most challenging issues encountered with these modalities is low effectiveness, as well as normal tissue toxicity for chemo-radiation therapy. The use of some agents as adjuvants has been suggested to improve tumor responses and also alleviate normal tissue toxicity. Resveratrol, a natural flavonoid, has attracted a lot of attention for the management of both tumor and normal tissue responses to various modalities of cancer therapy. As an antioxidant and anti-inflammatory agent, in vitro and in vivo studies show that it is able to mitigate chemo-radiation toxicity in normal tissues. However, clinical studies to confirm the usage of resveratrol as a chemo-radioprotector are lacking. In addition, it can sensitize various types of cancer cells to both chemotherapy drugs and radiation. In recent years, some clinical studies suggested that resveratrol may have an effect on inducing cancer cell killing. Yet, clinical translation of resveratrol has not yielded desirable results for the combination of resveratrol with radiotherapy, targeted therapy or immunotherapy. In this paper, we review the potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Ameneh Jafari ◽  
Mostafa Rezaei-Tavirani ◽  
Behrouz Farhadihosseinabadi ◽  
Hakimeh Zali ◽  
Hassan Niknejad

AbstractCancer is a leading cause of death in both developed and developing countries, and because of population growth and aging, it is a growing medical burden worldwide. With robust development in medicine, the use of stem cells has opened new treatment modalities in cancer therapy. In adult stem cells, mesenchymal stem cells (MSCs) are showing rising promise in cancer treatment due to their unique properties. Among different sources of MSCs, human amniotic fluid/membrane is an attractive and suitable reservoir. There are conflicting opinions about the role of human amniotic membrane/fluid mesenchymal stem cells (hAMSCS/hAFMSCs) in cancer, as some studies demonstrating the anticancer effects of these cells and others suggesting their progressive effects on cancer. This review focuses on recent findings about the role of hAMSCs/hAFMSCs in cancer treatment and summarizes the suppressing as well as promoting effects of these cells on cancer progression and underling mechanisms.


1980 ◽  
Vol 335 (1 Thermal Chara) ◽  
pp. 311-326 ◽  
Author(s):  
R. Cavaliere ◽  
G. Moricca ◽  
F. DiFilippo ◽  
A. Caputo ◽  
G. Monticelli ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1151
Author(s):  
Lu Tang ◽  
Jing Li ◽  
Qingqing Zhao ◽  
Ting Pan ◽  
Hui Zhong ◽  
...  

The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.


BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S47-S47
Author(s):  
Ashy Rengit

AimsIdentify common risk factors for longterm cognitive dysfunction in PBTS (paediatric brain tumour survivors) Examine how various paediatric cancer treatment modalities affect cognitive outcomes Consider baseline features which may increase the risk of cognitive dysfunction in PBTSMethodCurrent research into the neuropsychiatric sequelae of childhood brain tumours is limited, therefore review of the literature was conducted to identify research within this field.DatabasesGoogle Scholar - papers accessed via the University of Brighton or Sussex online libraryNICE HDAS - HMIC, AMED, MEDLINE, BNI, PsycINFO, CINAHL, Pubmed, EMBASE & EMCAREMendeley reference manager - papers for background readingSearch termsPICO(T) method - Population (Cancer Survivors), Intervention (Cancer Treatment), Comparison (Brain tumour), Outcome (Cognitive dysfunction) & Time (Childhood & adolescence) Boolean operators (AND/OR), truncation and wildcard search functions were also utilised.Inclusion criteria; no limits on date, study type or gender, however, study results were limited by age - as the research focus was restricted to children and adolescents.Excluded results; papers which did not meet inclusion criteria, duplicate studies, studies measuring non-cognitive cancer outcomes or investigating non-cortical tumours, non-English language studies with no available English translations.ResultCommon risk factors - certain tumour types (glioneuronal tumours or gliomas) or inner cortical tumour sites e.g. were more vulnerable to epileptogenesis. In particular, seizures which were prolonged and treatment-resistant were associated with a greater degree of cognitive dysfunction.Impact of various cancer treatment modalities - overall results understandably suggested that patients are more likely to develop cognitive deficits following brain tumour treatment. In particular, partial tumour resection (especially if epileptogenic), whole-brain irradiation, cranial radiotherapy and chemotherapy were more likely to impact cognitive function.Baseline features that may increase likelihood of cognitive dysfunction e.g. intellectual disability or education level were not noted in the reviewed literature.ConclusionCancer is one of the leading causes of global child mortality, and younger populations often present to paediatric oncology services with brain tumour involvement. Current childhood brain tumour research has begun to recognise that many young survivors develop into adulthood with cognitive sequelae impacting quality of life measures. However, existing evidence is also limited and requires further research to produce a standardised clinical tool for screening various risk factors which may increase longterm risk of cognitive dysfunction and subsequent difficulties with daily life.


2021 ◽  
Vol 06 ◽  
Author(s):  
Adnan Badran ◽  
Joelle Mesmar ◽  
Nadine Wehbe ◽  
Riham El Kurdi ◽  
Digambara Patra ◽  
...  

: Breast cancer remains one of the most common cancers in women worldwide, and despite significant improvements in treatment modalities, the prognosis of this cancer is still poor. Herbs and plant extracts have been associated with various health benefits, and traditional folk medicine is still receiving great interest among patients as proven by accumulated records, tolerable side effects of herbal compounds compared to their synthetic counterparts, and low cost. Curcumin is a polyphenol identified as the main active ingredient in turmeric and has been used in the treatment of various diseases and ailments. Additionally, the pharmacological activities of curcumin on many cancers have been investigated substantially due to its ability to regulate many signaling pathways involved in cancer tumorigenesis and metastasis. However, the low solubility and bioavailability of curcumin limit its benefits, urging the need for new curcumin formulations and delivery systems. Nanotechnology has been widely publicized in cancer treatment not only to overcome the limitations of poorly soluble and physiologically unstable compounds but also to improve the delivery of the drug to the diseased site and cellular uptake. In this review, we summarized the main anti-tumor effect of curcumin and its mode of action on breast cancer and focused on the anticancer efficacy of various and recent curcumin nanoformulations and delivery systems. Such nanotechnological systems could pave the way to address a new future direction in this research area, enhancing the therapeutic potential of curcumin in the treatment of breast cancer. In the next few years, there will be more focus on developing curcumin-based materials for breast cancer treatment.


2021 ◽  
pp. 47-58
Author(s):  
N.S. Rathore ◽  
N.L. Panwar

Sign in / Sign up

Export Citation Format

Share Document